GRDN vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
GRDN presents a stark divergence between fundamental value and market price, with a Piotroski F-Score of 4/9 indicating only stable financial health. The stock is trading at a massive premium, with a current price of $37.93 compared to a Graham Number of $7.55 and an Intrinsic Value of $5.46. While growth metrics and analyst recommendations are strongly bullish, they are heavily offset by aggressive insider selling totaling over $419 million. The combination of extreme overvaluation and bearish insider sentiment outweighs the current growth trajectory.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
GRDN vs MRK: Head-to-Head Comparison
This page compares Guardian Pharmacy Services, Inc. (GRDN) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.